⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

Hepatitis B is highly treatable, and most people live a normal lifespan. A safe, once-daily pill (tenofovir or entecavir) pushes the virus down to undetectable levels in nearly everyone who takes it consistently. That halts — and often reverses — liver scarring and sharply lowers the risk of cirrhosis and liver cancer.
It is usually controlled, not cured — so treatment is often long-term. Unlike hepatitis C (which is cured in weeks), hepatitis B is kept in check with ongoing therapy. Never stop your pills on your own. Stopping abruptly can cause a dangerous liver flare.
Not everyone needs treatment right away — but everyone needs monitoring. Whether you start a pill now depends on your viral load (HBV DNA), your liver enzyme (ALT), the amount of scarring, your age, and your family history of liver cancer. Even if you are not on treatment, you need regular checkups for life.
Hepatitis B can cause liver cancer even without cirrhosis. This is what makes it different from most liver diseases. If you are in a higher-risk group, you need a liver ultrasound (sometimes with a blood test called AFP) about every 6 months to catch any cancer early, when it is most treatable.
Get everyone close to you tested and vaccinated. Hepatitis B is preventable with a safe vaccine. Household members, sexual partners, and newborns should be tested and vaccinated. It is not spread by sharing food, hugging, coughing, or casual contact.
Mother-to-baby spread can almost always be stopped. A birth-dose vaccine plus an immune-globulin shot (HBIG) given to the newborn within 12 hours of birth — together with an antiviral for mothers with a high viral load in late pregnancy — prevents nearly all transmission.
Ask to be tested for hepatitis D (delta) at least once. Delta is a more aggressive "partner" virus that only infects people who already have hepatitis B. Every person with hepatitis B should be checked for it. As of May 2026, the United States finally has its first approved treatment for hepatitis D.
Tell every doctor you have hepatitis B before chemotherapy, steroids, or immune-suppressing drugs. These treatments can "wake up" the virus and cause a serious flare. A protective antiviral started beforehand prevents this. This is one of the most overlooked safety steps in all of medicine.
Protect your liver in everyday ways. Avoid alcohol, keep a healthy weight, get vaccinated against hepatitis A, and check every new medicine and herbal supplement for liver safety. These steps work alongside your antiviral.
A real cure is on the horizon. New medicines aimed at a "functional cure" (clearing the virus so you can stop therapy for good) are advancing through large clinical trials. They are not approved yet, but the field is moving fast — and today's pills keep your liver safe in the meantime.

▼ Collapse

Understanding Hepatitis B: An Overview

Hepatitis B is an infection of the liver caused by the hepatitis B virus (HBV). For most adults who catch it, the body clears it within a few months and they recover fully. But in some people — especially those infected at birth or in early childhood — the virus settles in for the long term. That is called chronic hepatitis B, and it is what this guide is about.

Worldwide, roughly 254 million people live with chronic hepatitis B. Many do not know it, because the infection is usually silent for years or even decades — you can feel completely well while the virus quietly affects your liver. That silence is exactly why testing matters: finding it early lets you protect your liver before any damage is done.

The big picture in one sentence. Chronic hepatitis B is a manageable, long-term condition: with the right combination of monitoring, antiviral pills when needed, and liver-cancer surveillance, the great majority of serious outcomes can be prevented — and most people live full, normal lives.

How hepatitis B is — and is not — spread

HBV travels through blood and certain body fluids. The most common routes are:

From mother to baby at birth (the leading cause worldwide).
Sexual contact with an infected partner.
Blood-to-blood contact — sharing needles, certain medical or dental procedures in places without strict infection control, or sharing personal items like razors or toothbrushes.

It is not spread by hugging, kissing on the cheek, sharing meals or utensils, coughing, sneezing, or breastfeeding (when the proper newborn shots are given). Understanding this is important: people with hepatitis B are safe to live, work, and share a home with. The stigma around the virus causes real harm and is not based on how it actually spreads.

The phases of chronic hepatitis B

One of the most confusing things about hepatitis B is that it is not one fixed state. It moves through phases over a lifetime, and your doctor uses your blood tests to figure out which phase you are in. The phase — not just having the virus — determines whether you need treatment now or careful watching.

Phase 1 — "Immune-tolerant" (HBeAg-positive chronic infection). The virus is replicating a lot (very high HBV DNA), but the immune system is largely ignoring it, so the liver enzyme ALT is normal and there is little inflammation. Common in younger people infected at birth. Often monitored rather than treated — though newer guidelines are re-examining this.
Phase 2 — "Immune-active" (HBeAg-positive chronic hepatitis). The immune system starts attacking infected liver cells. ALT rises, inflammation increases, and scarring can build. This phase usually needs treatment.
Phase 3 — "Inactive carrier" (HBeAg-negative chronic infection). The virus is mostly quiet: low HBV DNA, normal ALT, little ongoing damage. Many people stay here for years and are monitored. The lowest-risk phase — but it still needs surveillance because it can reactivate.
Phase 4 — "Immune-escape" (HBeAg-negative chronic hepatitis). The virus mutates so it no longer makes a marker called HBeAg, but it keeps replicating and damaging the liver. ALT and HBV DNA fluctuate. This phase usually needs treatment.

Some people do not fit neatly into one phase — doctors sometimes call this the "grey zone" or "indeterminate" phase. That is normal, and it is one reason monitoring over time (not a single snapshot) is so important.

Why early identification changes everything

Because chronic hepatitis B is usually silent yet can slowly progress to cirrhosis — and can cause liver cancer even without cirrhosis — finding it early is the single most powerful thing you can do. Once it is found, the path forward is clear: either start antiviral pills, or monitor carefully with regular liver-cancer surveillance. Both paths prevent the great majority of severe outcomes. The U.S. Centers for Disease Control and Prevention now recommends that every adult be screened for hepatitis B at least once in their lifetime.

Important disclaimer. This guide is for education and to help you have better conversations with your medical team. It is not a substitute for personal medical advice. Hepatitis B care is highly individual, and the science is advancing quickly. Always make decisions with a doctor who knows your full situation — ideally a liver specialist (hepatologist) or an infectious-disease or gastroenterology physician with hepatitis B experience.

Do I have acute hepatitis B that my body may clear, or chronic hepatitis B that needs long-term follow-up?
Which phase of chronic hepatitis B am I in right now, and how do you know?
Does my phase mean I should start treatment now, or monitor carefully?
Should I be seeing a liver specialist (hepatologist), and can you refer me?
How often will I need blood tests and checkups going forward?
Who in my family and household should be tested and vaccinated?

Your Diagnosis & Understanding Your Blood-Test Results

Hepatitis B is diagnosed and monitored almost entirely through blood tests. The results can look like alphabet soup, but each marker tells a specific part of your story. Understanding them will make you a far more confident partner in your own care.

The key markers, explained simply

Test (marker)	What it means in plain language
HBsAg (surface antigen)	The main flag that you currently have the hepatitis B virus. If it is positive for more than 6 months, you have chronic hepatitis B. The whole goal of a "functional cure" is to make this marker disappear for good.
anti-HBs (surface antibody)	A sign of immunity — either from the vaccine or from clearing a past infection. If you have this and nothing else positive, you are protected and not infectious.
anti-HBc (core antibody)	A footprint that says you have been exposed to the actual virus at some point (it does not come from the vaccine). "Total anti-HBc" stays positive for life. An "IgM" version suggests a recent or new infection.
HBeAg (e-antigen)	A marker that usually signals the virus is replicating actively and you may be more infectious. Losing it (and developing anti-HBe) is generally a good sign.
anti-HBe	Antibody that usually appears as the virus becomes less active — often a step in the right direction.
HBV DNA (viral load)	The actual amount of virus in your blood, measured in international units per milliliter (IU/mL). This is the number your doctor watches most closely to decide on treatment and to confirm a pill is working (the goal is "undetectable").
ALT (a liver enzyme)	A blood marker of liver inflammation or injury. A persistently high ALT suggests the immune system is actively battling the virus and the liver is taking damage.

Two numbers do most of the work. When deciding whether you need treatment, your doctor focuses heavily on your HBV DNA (viral load) and your ALT (liver inflammation), then layers in your HBeAg status, the amount of scarring, your age, and your family history.

HBsAg positive, anti-HBs negative → you have the virus (active infection).
HBsAg negative, anti-HBs positive, anti-HBc positive → you had hepatitis B in the past and your body cleared it; you are now immune.
HBsAg negative, anti-HBs positive, anti-HBc negative → you are immune from the vaccine (never infected).
"Isolated" anti-HBc positive (only the core antibody) → needs interpretation; can reflect a resolved infection, a window period, or rarely "occult" infection. Your doctor may order an HBV DNA test.

Tests you should have at least once after diagnosis

A complete first work-up usually includes more than the basic markers. Ask whether you have been checked for all of these:

HBV DNA (viral load) and liver enzymes (ALT, AST).
HBeAg / anti-HBe to help assign your phase.
Hepatitis D (anti-HDV) — every person with hepatitis B should be tested at least once (more on this in the Hepatitis D section).
HIV and hepatitis C — because they share routes of spread and change the treatment plan.
Hepatitis A immunity — so you can be vaccinated if you are not protected.
A measure of liver scarring (fibrosis) — usually a painless ultrasound-based scan called FibroScan (elastography), sometimes blood-based scores. This tells you how much, if any, scarring has occurred.
A liver ultrasound as a baseline, especially if you are in a liver-cancer risk group.

What "fibrosis staging" means

Fibrosis is liver scarring, staged roughly from F0 (none) to F4 (cirrhosis). You do not usually need a needle biopsy anymore — a FibroScan measures liver stiffness in minutes and is a good guide. Knowing your fibrosis stage is one of the biggest factors in deciding whether to treat now, because more scarring means more reason to start antivirals promptly.

A note on lab numbers. "Normal" ALT ranges and HBV DNA thresholds differ slightly between labs and guidelines, and your doctor interprets them in the context of your whole picture — not as a single pass/fail line. Do not try to self-diagnose your phase from a single result.

This is a lot of tests across possibly several visits. A caregiver can help enormously by keeping a simple running log of results (date, HBV DNA, ALT, HBeAg status, FibroScan score) so trends are visible over time. Bring this log to every appointment. Ask the clinic for access to the patient portal, where results are usually posted, and help your loved one read them without alarm — numbers move around, and one abnormal value rarely means an emergency.

What is my HBV DNA (viral load) number, and is it high, medium, or low?
What is my ALT, and is it normal or elevated?
Am I HBeAg-positive or HBeAg-negative, and what does that mean for me?
Have I been tested for hepatitis D, HIV, and hepatitis C? Am I immune to hepatitis A?
What is my fibrosis stage (FibroScan score), and do I have any cirrhosis?
Can you write down my key numbers so I can track them over time?
Based on all of this, what phase am I in, and what happens next?

Who Needs Treatment & How Antiviral Therapy Works

Here is the reassuring core of hepatitis B care: when treatment is needed, it is usually a single, well-tolerated pill taken once a day, and it works in nearly everyone who takes it consistently. The harder question is often not how to treat but whether and when — because not everyone needs to start right away.

Who needs treatment now, and who is monitored

Your doctor weighs several factors together, guided by major recommendations (the 2025 AASLD/IDSA guideline in the U.S., 2025 EASL in Europe, and WHO 2024 globally). In general, treatment is recommended or strongly considered when:

You have cirrhosis (any amount of detectable virus) — treat regardless of other numbers.
Your ALT is elevated and your HBV DNA is high (the "immune-active" phases), meaning the virus is actively damaging your liver.
You have significant fibrosis (scarring) even if ALT is only mildly up.
You are older (risk rises with age) or have a family history of liver cancer.
You are pregnant with a high viral load (to prevent passing it to your baby).
You are about to start chemotherapy or immune-suppressing drugs (to prevent reactivation).

People who are typically monitored rather than treated include younger people in the quiet "immune-tolerant" or "inactive carrier" phases with normal ALT and no significant scarring. Importantly, newer guidelines have been lowering the bar to treat — the WHO 2024 update notably broadened who is eligible, and the 2025 AASLD/IDSA guideline re-examined treating some people previously left untreated. The trend is toward treating more people, earlier.

Monitoring is not "doing nothing." If you are not on treatment, you still need regular blood tests (typically every 3–6 months at first, then often every 6–12 months) and liver-cancer surveillance if you are in a risk group. Phases change, and the plan can change with them.

The first-line pills (preferred for most people)

Three once-daily antivirals are the modern standard. They are extremely effective at suppressing the virus, and resistance to them is rare even over many years — which is exactly why older drugs were replaced.

Pill	What to know
Tenofovir disoproxil fumarate (Viread / TDF)	Very effective, very low resistance, inexpensive as a generic. Long track record, including in pregnancy. Needs attention to kidney and bone health over the long term, so your doctor monitors these.
Tenofovir alafenamide (Vemlidy / TAF)	A newer form of tenofovir that is gentler on the kidneys and bones. Often preferred if you have kidney concerns, osteoporosis, or are older. Usually more expensive than generic TDF.
Entecavir (Baraclude)	Very effective, very low resistance, available as a generic. A good choice for many, including some with kidney concerns (dose is adjusted). Avoided if you previously took and became resistant to lamivudine, because resistance can carry over.

The single most important safety rule. Do not stop your antiviral on your own, and do not let prescriptions lapse. Missing doses or stopping suddenly can trigger a withdrawal flare — a surge of the virus and liver inflammation that can be severe or even life-threatening. If cost, side effects, or anything else makes it hard to keep taking your pill, tell your doctor so the plan can be adjusted safely.

A finite course of injection (for selected people)

Peginterferon alfa-2a (Pegasys) is a weekly injection given for about 48 weeks. Unlike the daily pills, it is a defined course: you take it for a set time and then stop. For the right person, it offers a chance of lasting control after treatment ends — and even a chance of clearing the surface antigen (HBsAg). The trade-off is more side effects (flu-like symptoms, mood changes, low blood counts), so it is not for everyone. It is not used in advanced (decompensated) cirrhosis or during pregnancy. Response is more likely with certain virus genotypes and lower baseline HBsAg, which your doctor can check.

Older pills, now used rarely

Lamivudine, adefovir, and telbivudine were important in the past but are no longer first-line, because the virus can become resistant to them. They have largely been replaced by tenofovir and entecavir. If you started one of these years ago, ask whether you should switch.

What treatment is trying to achieve

Undetectable HBV DNA — achievable in nearly all adherent patients. This is the main day-to-day goal and it is what protects your liver.
Normal ALT — meaning the liver inflammation has settled.
HBeAg seroconversion (for those who start HBeAg-positive) — losing HBeAg and gaining anti-HBe, a meaningful milestone.
Functional cure (sustained loss of HBsAg) — the hardest and best outcome, currently uncommon with standard pills but the target of new drugs in trials.

Long-term, but not forever-without-question. Most people on pills stay on them indefinitely, and that is safe. But research is actively exploring which long-suppressed patients might one day stop safely (sometimes prompting a helpful immune response). For now, any stopping must be doctor-supervised, with close monitoring for flares.

Avoid alcohol — it adds direct injury on top of the virus.
Keep a healthy weight and good metabolic health — fatty-liver disease piles damage onto hepatitis B.
Get vaccinated against hepatitis A if you are not already immune.
Review every medicine and supplement with your doctor or pharmacist for liver safety — including over-the-counter products and herbal remedies, some of which can harm the liver or interact with your antiviral.
Take your pill at the same time daily and build it into a routine so doses are not missed.

Because missing doses can cause flares, the most valuable thing a caregiver can do is help make the daily pill automatic and uninterrupted. Practical steps: set a shared daily reminder; keep a few days' buffer supply; sign up for automatic pharmacy refills and refill reminders; and watch the calendar so prescriptions never lapse. If your loved one is struggling with cost, side effects, or simply remembering, treat that as something to solve with the doctor, not a failure to scold. Many branded antivirals have patient-assistance programs, and generic tenofovir and entecavir are inexpensive — cost should rarely be a true barrier, but it sometimes silently is.

Based on my numbers, do I need to start treatment now, or can we monitor?
If I start, which pill is safest for me given my kidneys, bones, age, and any past medications?
Is my treatment likely to be long-term or lifelong? What would make it possible to stop someday?
What exactly happens if I miss doses or run out — and how do I avoid that?
Am I a candidate for a finite course of peginterferon instead of daily pills?
How will we know the treatment is working, and how often will you check?
Which of my current medicines or supplements should I be cautious about?

Cirrhosis, Liver Cancer Screening & Advanced Disease

This section covers what happens if hepatitis B has caused more advanced liver damage — and, just as importantly, how regular screening catches problems early so they can be treated. The most important message here is hopeful: with modern antivirals and surveillance, far fewer people ever reach advanced disease, and many serious problems are caught when they are still very treatable.

Cirrhosis

Cirrhosis is advanced, widespread liver scarring. It is divided into:

Compensated cirrhosis — the liver is scarred but still doing its job. Many people feel well and live for years. Antivirals are recommended for everyone with cirrhosis, and they can actually reduce scarring over time.
Decompensated cirrhosis — the liver is struggling, with complications such as fluid buildup in the belly (ascites), confusion (encephalopathy), or bleeding from enlarged veins (varices). This needs specialist care and transplant evaluation. Peginterferon is not used here, but antiviral pills are still important.

Red flags — seek emergency care (call 911 or go to the ER): yellowing of the eyes or skin (jaundice), confusion or unusual drowsiness, vomiting blood or black tarry stools, sudden severe abdominal swelling, or severe abdominal pain. These can signal a liver flare or a complication of advanced disease.

Liver cancer screening — the HBV-specific point

Here is what sets hepatitis B apart from almost every other liver disease: it can cause liver cancer (hepatocellular carcinoma, or HCC) even in people who do not have cirrhosis. The virus integrates into liver cells in a way that can drive cancer directly. That is why screening is not just for people with cirrhosis.

If you are in a higher-risk group, the recommendation is a liver ultrasound every 6 months, sometimes paired with a blood test called AFP (alpha-fetoprotein). This is quick, painless, and catches most cancers early, when they are small and curable.

Who needs 6-monthly HCC screening

Anyone with cirrhosis, from any cause, including hepatitis B.

Higher-risk people without cirrhosis, which by widely used criteria includes: Asian men over about 40; Asian women over about 50; people of African ancestry from a younger age (often cited around 20); anyone with a family history of liver cancer; and people with persistently high HBV DNA or significant inflammation. Your doctor will tell you which apply to you, sometimes using a risk score.

Treatment lowers cancer risk — but does not erase it. Antiviral pills meaningfully reduce the chance of liver cancer, which is one of their greatest benefits. But the risk does not fall to zero, so you continue screening even while on effective treatment if you are in a risk group.

Liver cancer caught early has many treatment options, including surgery to remove the tumor, ablation (destroying it with heat or other energy), procedures that block its blood supply, liver transplant, and newer drug therapies for more advanced cases. The earlier it is found, the more options you have — which is the whole reason for 6-monthly screening. Care is best coordinated at a center with a liver-cancer team. (Detailed cancer treatment is beyond this guide; ask for referral to a hepatology/oncology liver tumor board.)

Liver transplant

For end-stage cirrhosis or certain liver cancers that cannot be controlled otherwise, a liver transplant can be life-saving. Hepatitis B is one of the success stories of transplantation: with lifelong antiviral therapy (sometimes plus hepatitis B immune globulin, HBIG), the new liver can be protected from reinfection, and outcomes are very good. In the Mountain West, the University of Utah is the regional liver transplant center.

Two concrete ways caregivers protect a loved one with hepatitis B: (1) Guard the 6-month ultrasound. It is easy to skip an imaging appointment when someone feels fine — but feeling fine is exactly when screening saves lives. Put it on a recurring calendar and help with scheduling and transport. (2) Learn the red flags above. Jaundice, confusion, belly swelling, and vomiting blood are emergencies. If you are supporting someone before or after a transplant, you become a key part of the team: tracking the many medications, watching for signs of rejection or infection, and getting to appointments. Ask the transplant center for caregiver education — they expect and welcome it.

Do I have any cirrhosis? If so, is it compensated or decompensated?
Am I in a group that needs liver-cancer screening — and how often?
What does my screening involve (ultrasound, AFP), and when is my next one due?
Even though I'm on treatment, do I still need cancer screening? (Usually yes.)
What warning signs should send me to the emergency room?
If my liver disease is advanced, should I be evaluated for transplant, and where?

Preventing Spread: Vaccination, Household Protection & Pregnancy

Hepatitis B is one of the few serious chronic viruses that is vaccine-preventable. That means you can protect the people you love — and, if you are pregnant, almost completely protect your baby. This is some of the most empowering information in the whole guide.

The vaccine works — protect your circle

A safe, effective hepatitis B vaccine has existed for decades. The World Health Organization has recommended universal infant vaccination since 1992, and it has dramatically reduced new infections and even childhood liver cancer (Taiwan's pioneering program was the first to prove this). If you have hepatitis B:

Make sure your household members and sexual partners are tested. Those who are not already infected or immune should be vaccinated.
Until partners are confirmed immune, use condoms to reduce sexual transmission.
Do not share items that can carry blood: razors, toothbrushes, nail clippers, glucose-testing lancets.
Cover cuts, and clean blood spills with appropriate disinfectant.

You are not a danger to be around. Hepatitis B is not spread by hugging, sharing food or drinks, coughing, sneezing, or everyday contact. Vaccinating close contacts is about the few blood-and-fluid routes — not about avoiding normal life together.

Beyond the classic vaccines, newer options can protect faster or help people who did not respond to older vaccines: an adjuvanted two-dose vaccine (which completes protection in about a month rather than six) and a three-antigen vaccine that can work in some people who failed standard vaccination. If you or a contact did not develop immunity after a full series, ask about revaccination strategies and these newer products.

Pregnancy: stopping mother-to-baby spread

Mother-to-baby transmission at birth is the leading cause of chronic hepatitis B worldwide — and it is also one of the most preventable. The modern, layered approach prevents transmission in nearly all cases:

Screen every pregnancy. All pregnant people should be tested for HBsAg. If positive, the viral load (HBV DNA) is checked.
Antiviral for high viral load. If the mother's HBV DNA is high (commonly defined as above 200,000 IU/mL), tenofovir (TDF) is offered to lower the viral load before delivery. It is typically started in the third trimester, often around gestational week 28; in some settings where infant immune globulin is not available, guidelines support starting earlier. Tenofovir has a strong safety record in pregnancy.
Protect the newborn within 12 hours of birth. The baby receives both the hepatitis B birth-dose vaccine and hepatitis B immune globulin (HBIG), then completes the vaccine series. This combination is the heart of prevention.
Confirm the baby is protected. After the series, the infant is tested to confirm immunity and that they did not become infected.

Breastfeeding is safe. With the newborn's birth-dose vaccine and HBIG in place, breastfeeding is recommended and safe — including for mothers taking tenofovir, which passes into breast milk only in tiny amounts. Do not let hepatitis B stop you from breastfeeding.

Some people experience a hepatitis B "flare" (rising ALT) in the months after giving birth, as the immune system shifts back. If antiviral was started only to protect the baby, your doctor will decide whether to continue or stop it — and if stopping, will monitor your liver tests closely for several months. Keep your postpartum liver follow-up appointments even amid the busyness of a new baby.

A caregiver can take ownership of one high-impact task: making sure every household member and sexual partner gets tested and, if needed, vaccinated, and that any newborn receives both shots within 12 hours of birth. Keep a simple checklist of who has been tested, who is immune, and who still needs vaccine doses. For a new baby, confirm with the delivery team in advance that the birth-dose vaccine and HBIG are planned — do not assume; ask explicitly.

Which of my household members and partners should be tested and vaccinated?
How do I know when a partner is fully protected so we can stop using condoms?
If I'm pregnant: what is my viral load, and do I need tenofovir to protect my baby?
Is my delivery team set up to give my newborn the birth-dose vaccine and HBIG within 12 hours?
Can I breastfeed, including while taking tenofovir?
After delivery, how will you watch for a flare, and will I continue treatment?
If someone in my family didn't respond to the vaccine, what are the next steps?

Hepatitis D (Delta): The Partner Virus Everyone with Hepatitis B Should Be Tested For

Hepatitis D, also called the delta virus (HDV), is a smaller, more aggressive virus that can only survive in people who already have hepatitis B — it borrows the hepatitis B surface antigen (HBsAg) to spread. When the two viruses are present together, liver disease tends to progress faster, with a higher risk of cirrhosis and liver cancer. It is considered the most severe form of viral hepatitis.

Get tested at least once. Every person with hepatitis B (anyone HBsAg-positive) should be tested for hepatitis D at least once, with an anti-HDV antibody test. If that is positive, an HDV RNA test confirms active infection. Many people with delta do not know they have it — testing is the only way to find out.

A major change in 2026: the first U.S. treatment

For years, the United States had no FDA-approved treatment specifically for hepatitis D, even though the virus is so serious. That changed on May 22, 2026, when the FDA granted accelerated approval to bulevirtide-gmod (brand name Hepcludex), made by Gilead — the first and only approved treatment for chronic hepatitis D in the U.S.

Bulevirtide is a once-daily injection under the skin. It works as an "entry inhibitor": it blocks the doorway (a liver-cell receptor called NTCP) that both HDV and HBV use to enter liver cells, helping to bring the delta virus under control and calm liver inflammation. It had already been available in Europe for several years before its U.S. approval.

Important safety note about bulevirtide. Its label carries a boxed warning: stopping the drug can cause severe flares of hepatitis D and hepatitis B, so it must be managed by a specialist with close monitoring — never stopped on your own. It is approved for adults without cirrhosis or with compensated (well-functioning) cirrhosis.

Other treatment for delta

Peginterferon alfa-2a (the weekly injection) has also been used for hepatitis D, sometimes alongside other approaches, and remains an option in certain situations. Because delta is complex and the treatment landscape is changing quickly, care is best directed by a hepatologist or infectious-disease specialist with delta experience. There are also promising delta drugs still in clinical trials.

Hepatitis D is concentrated in certain parts of the world — including Mongolia (the highest burden), Central and West Africa, parts of Eastern Europe and the Mediterranean, and the Amazon basin. If you or your family come from one of these regions, testing for delta is especially important. But because anyone with hepatitis B can have it, testing is recommended for everyone with HBV regardless of background.

If your loved one has hepatitis B but has never been tested for hepatitis D, that is a concrete, high-value question to raise at the next visit. If they do have delta and start bulevirtide, the medication is a daily self-injection — help them learn the technique from the clinic, set up a routine, and (as with all hepatitis treatment) make sure it is never stopped without the specialist's guidance because of the flare risk.

Have I ever been tested for hepatitis D? If not, can we test now?
If my anti-HDV is positive, do I need the HDV RNA test to confirm active infection?
Am I a candidate for bulevirtide, and where would I get it?
What monitoring do I need while on delta treatment, and what are the risks of stopping?
Should I see a specialist with specific experience in hepatitis D?

class="content-section" data-stage="cure-trials,trials">

The Search for a Cure & How to Find Clinical Trials

For the first time in the history of hepatitis B, medicines aimed at an actual cure are advancing through large, late-stage clinical trials. This is genuinely hopeful news — while keeping in mind that, as of mid-2026, these are not yet approved, and today's pills remain the standard that keeps your liver safe in the meantime.

What "functional cure" means

A true "sterilizing cure" — removing every last trace of the virus from the body — is not yet possible, because HBV hides a stubborn template inside liver cells. So researchers aim for the next best thing: a functional cure, defined as sustained loss of the surface antigen (HBsAg) so that you could stop therapy for good while the virus stays controlled. That is the finish line the new drugs are chasing.

The leading candidate: bepirovirsen

The drug furthest along is bepirovirsen (developed by GSK with Ionis), an "antisense" medicine that silences the virus's instructions to make its proteins, including HBsAg. In two large Phase 3 trials called B-Well 1 and B-Well 2, a finite course of bepirovirsen added to standard therapy achieved a functional cure in a meaningful share of people — roughly one in five overall (and more in those who started with lower HBsAg levels) — far above the roughly 1% per year seen with current pills alone. The results were published in the New England Journal of Medicine in 2026.

Where bepirovirsen stands now (mid-2026). It is under FDA Priority Review with a target decision date of October 26, 2026. It is not approved yet — so it is not something you can be prescribed today, but a decision is expected soon. Reviews are also underway in Europe, Japan, and China.

Other approaches in trials

siRNA "gene-silencing" drugs (such as elebsiran and xalnesiran) switch off the virus's protein production in a different way, usually tested in combination with other agents or immune boosters.
Capsid (core) assembly modulators interfere with the virus's ability to build itself.
Entry inhibitors (the same family as bulevirtide for delta) block the virus from getting into liver cells.
Immune-modulating therapies and therapeutic vaccines aim to re-train your immune system to control the virus on its own.

Most experts believe the eventual cure will be a combination of these — one to lower the surface antigen, another to wake up the immune system — much like combination therapy transformed HIV and hepatitis C.

How to find and join a clinical trial

If you are interested in trials, talk with your hepatologist first — they can tell you whether you might qualify and refer you to a study site. To search yourself:

Go to ClinicalTrials.gov and search "hepatitis B" plus your location, filtering for "recruiting." For hepatitis D, search "hepatitis delta."
The Hepatitis B Foundation (hepb.org) maintains plain-language information about the drug pipeline and trials.
Academic liver centers (in Utah, the University of Utah) often run or know of active trials.

These are real, registered studies you can look up on ClinicalTrials.gov by their NCT number. Listing them is for information only — it is not an endorsement, and recruiting status changes over time.

B-Well 1 (bepirovirsen, Phase 3): NCT05630807
B-Well 2 (bepirovirsen, Phase 3): NCT05630820
MYR301 (bulevirtide for hepatitis D, the Phase 3 trial behind the 2026 U.S. approval): NCT03852719
ENSURE (elebsiran + peginterferon, Phase 2): NCT05970289
Piranga (xalnesiran ± immunomodulator, Phase 2): NCT04225715

A full, audited trial table appears in the companion Clinical Guide.

Given my numbers (especially my HBsAg level), might I be a candidate for a functional-cure trial?
Are there hepatitis B or hepatitis D trials near me that are recruiting?
What would joining a trial involve, and what are the risks and time commitment?
Should I keep taking my current pill while we explore trials? (Almost always yes.)
When bepirovirsen's FDA decision comes, will it be appropriate for me?

For Caregivers: How to Help

Supporting someone with hepatitis B is mostly about a handful of concrete, high-impact tasks — and about reducing fear and stigma. You do not need a medical background to make a real difference.

The five things that matter most

Protect daily adherence. Missing antiviral doses or letting prescriptions lapse can cause a dangerous liver flare. Help build an unbreakable routine: a daily reminder, automatic refills, a buffer supply, and a watchful eye on the refill calendar.
Guard the 6-month liver-cancer ultrasound. It is easy to skip when your loved one feels fine — but that is exactly when it saves lives. Put it on a recurring calendar; help schedule and drive to it.
Get the household and partners tested and vaccinated — and make sure any newborn gets the birth-dose vaccine and HBIG within 12 hours of birth.
Reduce stigma. Hepatitis B is not spread by casual contact. Sharing meals, hugging, and normal family life are all completely safe. Saying this out loud, to family and to the person themselves, lifts a real emotional burden.
Know the emergency red flags. Yellowing eyes/skin, confusion, severe belly swelling, or vomiting blood — call 911. These can mean a flare or advanced liver disease.

Before any chemotherapy, steroids, or immune-suppressing treatment — speak up. If your loved one with hepatitis B (current or past) is about to start cancer treatment, rituximab, long-term steroids, or other immune-suppressing drugs, make sure the prescribing team knows about the hepatitis B. A protective antiviral started beforehand prevents reactivation. This step is missed surprisingly often, and caregivers can be the ones who catch it.

Supporting someone before or after a liver transplant

If your loved one needs a transplant, you become a core part of the team. That means helping track a long list of medications (including the antiviral that protects the new liver), watching for signs of rejection or infection, getting to frequent appointments, and supporting emotional recovery. Ask the transplant center for formal caregiver education — they plan for caregivers and will train you.

Taking care of yourself

Caregiving is a marathon. Use the patient portal to stay organized, lean on the resources in the next section, and remember that a steady, calm presence — not perfection — is what helps most.

What is the single most important thing I can do to help?
How can I get access to the patient portal and test results?
What symptoms should prompt me to call you — versus call 911?
Who do I contact, and how, if there's a problem after hours?
If my loved one needs other medical or dental procedures, what should those providers know about the hepatitis B?

Support, Specialty Centers, Failed Therapies, Access & References

This final section gathers the practical resources: where to get care (starting close to home in Utah and the Mountain West), an honest look at treatments that have not worked, how access differs around the world, a plain-language glossary, and the named sources behind this guide.

Failed & de-adopted therapies — an honest accounting

You will encounter claims online about ways to "cure" or "boost immunity against" hepatitis B. Here is what rigorous testing actually shows does not work, so you can avoid wasting money, hope, or your health.

Claim / therapy	What the evidence shows
Older antivirals as first-line (lamivudine, adefovir, telbivudine)	Not wrong historically, but the virus develops resistance to them. They have been replaced by tenofovir and entecavir and are no longer recommended as first choices.
Therapeutic vaccines alone (e.g., the GS-4774 yeast-based vaccine)	In trials, vaccinating people who already have hepatitis B did not clear or meaningfully lower the surface antigen on its own. Immune approaches now focus on combinations, still in research.
siRNA or antisense drugs as standalone cures	By themselves, these gene-silencing drugs rarely achieve lasting surface-antigen loss — which is why current trials combine them with immune boosters or interferon. Promising, but not a solo cure.
Herbal "liver detox" and supplement cures	No herbal product, supplement, or "detox" has been shown in rigorous trials to cure or control hepatitis B. Some — including certain traditional remedies and high-dose supplements — can actually injure the liver or interact with your antiviral. Always run supplements past your doctor or pharmacist. These are not a substitute for standard care.
Stopping antivirals to "cure" yourself	Dangerous. Stopping without supervision can cause a severe withdrawal flare. Any planned stop must be doctor-guided with close monitoring.

If you see a "cure" being sold: be skeptical. The only cure-directed medicines with real Phase 3 evidence (like bepirovirsen) are still in the regulatory pipeline and only available through approved channels or clinical trials — never through online sellers.

Specialty center directory

Hepatitis B is best managed by a hepatologist, or an infectious-disease or gastroenterology physician with hepatitis B experience. Phone numbers change; confirm before visiting. The listings below are starting points, not endorsements.

University of Utah Health — Hepatology / Liver Center (Salt Lake City). The region's academic liver program and the regional liver transplant center: antiviral therapy, FibroScan/elastography, 6-monthly HCC surveillance, hepatitis D evaluation, and transplant with post-transplant prophylaxis. Main line: 801-581-2000; Liver/GI clinic access often via 801-585-0303. (Confirm current numbers when scheduling.)
Intermountain Health — Gastroenterology / Hepatology and primary care (clinics across the Wasatch Front and southern Utah): hepatitis B testing, monitoring, and treatment. Reach via Intermountain's main scheduling or your local clinic.
Utah Department of Health & Human Services — Viral Hepatitis Program & Immunization Program: testing resources, hepatitis B vaccination (including birth-dose and catch-up), and linkage-to-care information.
Community & refugee health programs serving Asian, Pacific Islander, and African communities most affected by hepatitis B — culturally tailored testing, vaccination, and linkage. Ask about local "Know Hepatitis B" / Hep B Free efforts.
Maternal-fetal medicine / OB clinics (University of Utah, Intermountain): hepatitis B screening in pregnancy, third-trimester antiviral when indicated, and coordination of the newborn birth-dose vaccine and HBIG.

Major academic liver centers with deep hepatitis B and transplant programs include (representative, not exhaustive): the University of California San Francisco (UCSF) Liver Center; University of Michigan; Mount Sinai (New York); Stanford; Johns Hopkins; the Cleveland Clinic; Mayo Clinic (Rochester, Arizona, Florida); and Baylor (Texas). Many run functional-cure clinical trials. To find one near you, ask your doctor for a referral or search the Hepatitis B Foundation's liver-specialist directory.

The VA is one of the largest providers of viral hepatitis care in the U.S. and has extensive hepatitis B and C programs. If you are a veteran, ask your VA primary-care provider for hepatitis B testing and referral to VA hepatology/infectious disease. In Utah, the VA Salt Lake City Health Care System (George E. Wahlen VA Medical Center) provides specialty liver care; main line 801-582-1565. Hepatitis acquired in connection with military service may be relevant to service-connection claims — ask a Veterans Service Officer.

Care is delivered through provincial health systems and academic liver centers such as the Toronto Centre for Liver Disease (University Health Network), University of Alberta, and McGill (Montreal). First-line antivirals (tenofovir, entecavir) are available; drug coverage varies by province through public drug plans and private insurance, so confirm formulary coverage and any special-authorization requirements for branded agents like TAF.

Leading hepatitis B and hepatitis D programs exist worldwide, including in regions of highest burden: in Europe, centers associated with EASL in Germany, Italy, France, and Spain (and strong hepatitis D programs in Germany and Italy); across Asia-Pacific, major programs in Taiwan (pioneer of universal infant vaccination), South Korea, Japan, and mainland China; and growing programs across sub-Saharan Africa. The WHO coordinates global elimination efforts. For trials and specialist directories, start with the Hepatitis B Foundation (hepb.org).

International access & regulatory landscape

What is available — and affordable — differs by country. A few key points:

Therapy	Access notes by region
Tenofovir (TDF), entecavir	Approved and available almost everywhere, including as inexpensive generics. Globally, the binding problem is usually diagnosis and linkage to care, not drug cost.
Tenofovir alafenamide (TAF)	Approved in the U.S., EU, and many countries; generally costlier than generic TDF, with coverage rules that vary. China has also approved domestic tenofovir prodrugs (e.g., tenofovir amibufenamide).
Bulevirtide (Hepcludex) for hepatitis D	Approved in the EU since 2020 (2 mg dose) and newly approved in the U.S. on May 22, 2026 (8.5 mg dose) — the first U.S. delta treatment. Availability still differs sharply by country, a major global equity gap for the world's most severe viral hepatitis.
Bepirovirsen (functional-cure candidate)	Not yet approved anywhere as of mid-2026. Under FDA Priority Review (decision expected Oct 26, 2026) and parallel review in the EU, Japan, and China.

Why hepatitis B is a global story. Most of the ~254 million people with chronic hepatitis B live in the Western Pacific and African regions, where it is usually caught at birth or in early childhood. Birth-dose vaccination is the single most important prevention tool worldwide, and the WHO aims to eliminate viral hepatitis as a public-health threat by 2030. Different expert guidelines (AASLD/IDSA, EASL, APASL, WHO) agree on the core — first-line antivirals and HCC surveillance — while differing on exactly whom to treat; the WHO's 2024 update simplified and broadened eligibility to expand access.

Glossary (plain-language)

HBsAg (surface antigen): the main flag that you currently have the virus; its disappearance is the goal of a "functional cure."
anti-HBs: the antibody showing you are immune (from vaccine or recovery).
anti-HBc (core antibody): a footprint of past or present infection with the real virus (not from the vaccine).
HBeAg / anti-HBe: markers that help show how active the virus is.
HBV DNA (viral load): the amount of virus in your blood; the main number guiding treatment.
ALT: a liver enzyme; a marker of liver inflammation.
Fibrosis / cirrhosis: liver scarring; cirrhosis is the advanced, widespread stage.
FibroScan (elastography): a painless scan that measures liver stiffness to estimate scarring.
HCC (hepatocellular carcinoma): the main type of liver cancer; screened with ultrasound ± AFP.
AFP: a blood test sometimes used alongside ultrasound for cancer screening.
Functional cure: sustained loss of HBsAg, allowing therapy to stop while the virus stays controlled.
Withdrawal flare: a dangerous surge of virus and inflammation that can follow stopping antivirals abruptly.
HBIG (hepatitis B immune globulin): a shot of protective antibodies, given to newborns (and in some other situations) for immediate protection.
HDV (hepatitis D / delta): a more severe "partner" virus that only infects people who have hepatitis B.
Reactivation: the virus "waking up" and flaring, often triggered by immune-suppressing treatment.
NA / nucleos(t)ide analogue: the class of antiviral pills (tenofovir, entecavir).

Key references & sources

AASLD/IDSA Practice Guideline on Treatment of Chronic Hepatitis B — Ghany MG, Pan CQ, Lok AS, et al. Hepatology. 2026;83(4):974–997 (published online Nov 4, 2025). PMID 41186418. The current U.S. guideline.
EASL 2025 Clinical Practice Guidelines on the management of hepatitis B virus infection — Cornberg M, et al. Journal of Hepatology, 2025. The current European guideline.
WHO 2024 Guidelines for the prevention, diagnosis, care and treatment of people with chronic hepatitis B infection (expanded, simplified treatment eligibility).
CDC universal hepatitis B screening recommendation (MMWR, 2023): screen all adults at least once.
FDA approval of bulevirtide-gmod (Hepcludex) for chronic hepatitis D, May 22, 2026 — first U.S. delta treatment; based on the Phase 3 MYR301 trial (NCT03852719).
Bepirovirsen Phase 3 (B-Well 1 & 2) — published in the New England Journal of Medicine, 2026 (NCT05630807, NCT05630820); under FDA Priority Review, decision target Oct 26, 2026.
APASL clinical practice guidelines on the management of hepatitis B (Asia-Pacific).
Hepatitis B Foundation (hepb.org) — patient information, specialist directory, drug-watch / trial information.

Support & patient resources

Hepatitis B Foundation (hepb.org): trusted patient information, a "Liver Specialist Directory," and pipeline/trial updates. Patient-assistance programs can help with the cost of branded antivirals.
ClinicalTrials.gov: search active hepatitis B and hepatitis D trials.
CDC Viral Hepatitis and MedlinePlus: reliable general information and vaccination guidance.
Utah DHHS Viral Hepatitis & Immunization Programs: local testing, vaccination, and linkage to care.

Final disclaimer. This guide is educational and reflects the state of knowledge as of June 2026. It does not replace personal medical advice, diagnosis, or treatment. Hepatitis B care is highly individual and evolving — approvals, guidelines, and trial results change. Always confirm specifics, dosing, screening intervals, and eligibility with your own qualified healthcare professional, ideally a liver specialist. Never start or stop any medication based on this guide alone.

A realistic, hopeful close. Chronic hepatitis B is very manageable. Safe, inexpensive once-daily pills suppress the virus to undetectable levels in nearly everyone who takes them, halting and often reversing liver scarring and sharply reducing the risk of cirrhosis and liver cancer — so most people live full, normal lives. A vaccine prevents new infections, mother-to-baby transmission can be almost entirely prevented, and for the first time, medicines aimed at an actual cure are advancing through trials. With monitoring, treatment when needed, and surveillance, hepatitis B is a condition you can live well with.